Lubrizol forms alliance with Particle Sciences

LUBRIZOL LifeSciences, a leading supplier of advanced materials for the healthcare industry, and Particle Sciences, an integrated provider of drug development services have formed an alliance that is expected to be one of the most comprehensive in the pharmaceutical industry.

This alliance, following Lubrizol’s acquisition of contract manufacturer Vesta, offers customers a comprehensive solution providing a range of materials, drug development and commercial manufacturing services. It will mean that the group’s LifeSciences business now offers complete solutions for sustained, controlled release and combination products from polymer supply and drug product development through quality manufacturing services. 

Lubrizol LifeSciences now offers a combination of world class polymer technology, drug product development services, clinical supply, applications know-how and commercial manufacturing.

“We’ve broadened our offering and further reinforced our commitment to the pharmaceutical market,” said Jean Claude Deneuville, Lubrizol LifeSciences director of the Pharma Solutions business. “By joining forces with Vesta and working with Particle Sciences, we have further expanded our set of skills and brought full-service solutions to the market.”

The alliance was officially launched by Lubrizol LifeSciences (booth 1817) and Particle Sciences (booth 2911) at the American Association of Pharmaceutical Scientists (AAPS) conference (Nov. 2-6) at the San Diego Convention Center.

“Teaming up with both Vesta and Particle Sciences enables Lubrizol to leverage our core polymer chemistry into tailored solutions for novel implantable and dermal drug delivery systems and combination products to deliver improved patient outcomes,” said Joey Glassco, global market manager for Lubrizol LifeSciences.

Particle Sciences, based in Bethlehem, Pennsylvania, is one of the world's leading contract drug development and manufacturing organizations (CDMO). Its leadership in drug eluting product development and breadth of development technologies has earned it business with life sciences companies ranging from start-ups to more than half of the top 10 pharmaceutical and biotech leaders.

The recent acquisition of Vesta, a leading contract manufacturer to the medical device industry, broadens Lubrizol's life science manufacturing capabilities, applications and material portfolio with access to silicone polymers and a variety of thermoplastics utilized in medical devices, advanced wound care and drug eluting products such as subcutaneous implants and intravaginal rings.